Identifying microbially‐derived metabolites that may serve as biomarkers for health, or metabotyping, is a necessary step to understanding the role of the microbiome in human health. Ultimately, knowing what metabolites (including presence and quantity) matter for health can inform development of a nutritional strategy for health benefits and the prevention of adverse health outcomes such as metabolic syndrome, type 2 diabetes, and cardiovascular disease. The specific questions to be addressed in this project are: 1) What diet‐derived and gut‐derived metabolites and/or metabotypes have been linked to specific health outcomes or are markers of health outcomes?; and 2) What types of evidence are available on the relationship between those metabolites/metabotypes and specific health outcomes?
Institution: Johns Hopkins University
Principal Investigator: Karen Robinson, PhD
Year Awarded: 2020
This project was supported by the ILSI North America Gut Microbiome Committee